Evidence map›Paper›PMID 36980185›Full record

ArticleCells2023

Establishing 20S Proteasome Genetic, Translational and Post-Translational Status from Precious Biological and Patient Samples with Top-Down MS.

Angelique Sanchez Dafun, Dušan Živković, Stephen Adonai Leon-Icaza, Sophie Möller, Carine Froment, Delphine Bonnet, Adriana Almeida de Jesus, Laurent Alric, Muriel Quaranta-Nicaise, Audrey Ferrand and 8 more

Open access · goldFull text read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Angelique Sanchez DafunInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.ORCID 0000-0003-0559-850X
Dušan ŽivkovićInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.ORCID 0000-0001-5794-4422
Stephen Adonai Leon-IcazaInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.ORCID 0000-0002-7546-8228
Sophie MöllerInstitute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, 17475 Greifswald, Germany.
Carine FromentInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.
Delphine BonnetIRSD, Université de Toulouse, INSERM, INRAE, ENVT, Université de Toulouse III-Paul Sabatier (UPS), 31300 Toulouse, France.
Adriana Almeida de JesusTranslational Autoinflammatory Diseases Section, LCIM, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Laurent AlricInternal Medicine Department of Digestive Disease, Rangueil Hospital, Université de Toulouse III-Paul Sabatier (UPS), 31400 Toulouse, France.
Muriel Quaranta-NicaiseIRSD, Université de Toulouse, INSERM, INRAE, ENVT, Université de Toulouse III-Paul Sabatier (UPS), 31300 Toulouse, France.
Audrey FerrandIRSD, Université de Toulouse, INSERM, INRAE, ENVT, Université de Toulouse III-Paul Sabatier (UPS), 31300 Toulouse, France.ORCID 0000-0002-1057-8151
Céline CougouleInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.ORCID 0000-0002-6795-5448
Etienne MeunierInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.
Odile Burlet-SchiltzInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.ORCID 0000-0002-3606-2356
Frédéric EbsteinInstitute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, 17475 Greifswald, Germany.ORCID 0000-0002-3729-7878
Raphaela Goldbach-ManskyTranslational Autoinflammatory Diseases Section, LCIM, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Elke KrügerInstitute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, 17475 Greifswald, Germany.ORCID 0000-0002-2551-242X
Marie-Pierre BousquetInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.ORCID 0000-0003-2680-8932
Julien MarcouxInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III-Paul Sabatier (UPS), 31077 Toulouse, France.ORCID 0000-0001-7321-7436
Centre National de la Recherche Scientifique · FRUniversité Toulouse III - Paul Sabatier · FRUniversitätsmedizin Greifswald · DENational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mammalian 20S catalytic core of the proteasome is made of 14 different subunits (α1-7 and β1-7) but exists as different subtypes depending on the cell type. In immune cells, for instance, constitutive catalytic proteasome subunits can be replaced by the so-called immuno-catalytic subunits, giving rise to the immunoproteasome. Proteasome activity is also altered by post-translational modifications (PTMs) and by genetic variants. Immunochemical methods are commonly used to investigate these PTMs whereby protein-tagging is necessary to monitor their effect on 20S assembly. Here, we present a new miniaturized workflow combining top-down and bottom-up mass spectrometry of immunopurified 20S proteasomes that analyze the proteasome assembly status as well as the full proteoform footprint, revealing PTMs, mutations, single nucleotide polymorphisms (SNPs) and induction of immune-subunits in different biological samples, including organoids, biopsies and B-lymphoblastoid cell lines derived from patients with proteasome-associated autoinflammatory syndromes (PRAAS). We emphasize the benefits of using top-down mass spectrometry in preserving the endogenous conformation of protein modifications, while enabling a rapid turnaround (1 h run) and ensuring high sensitivity (1-2 pmol) and demonstrate its capacity to semi-quantify constitutive and immune proteasome subunits.

Indexed as

Proteasome Endopeptidase ComplexProtein Processing, Post-TranslationalAnimalsCell LineCytoplasmHumansMammalsMass SpectrometryProteasome Endopeptidase Compleximmunoproteasomelabel-free quantificationPRAASproteasomeproteoformtop-down proteomics

Identifiers

PMID36980185
PMCPMC10047880
OpenAlexW4323668302

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read167
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.